We are pleased to announce that our product development site in the
The ISO 13485 certification is an endorsement of the Quality Management System (QMS) that underpins the Company's position as a trusted manufacturer of medical devices. The accreditation is recognised on an international scale and is a critical part of gaining regulatory approval for our products. Moreover this development is important in enabling the Company to operate with greater capacity and improved efficiency and is a crucial step towards the development, manufacturing and distribution of our current products but also the ones included in our product pipeline portfolio.
For more information, please contact:
ir@aegirbio.com
About
The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment, while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs and suboptimal clinical outcomes.
The Company's tests for optimal dosing of biological drugs will be focused on neurological disorders, autoimmune diseases and cancer. In the first quarter of 2020,
For more information, please visit
Certified adviser for the company is Eminova Fondkommission AB | +468-684 211 00 | info@eminova.se
https://news.cision.com/aegirbio/r/aegirbio-uk-facility-iso-13485-compliant,c3724414
(c) 2023 Cision. All rights reserved., source